SCHEMBL267253

SCHEMBL267253

Cc1ccc(/C=N/NC(=O)c2cc(N3CCOCC3)ccc2NC(=O)c2cccc(CSCCO)c2)cc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.47
KDM4E B2RXH2 10/20 0.47
SLC34A2 O95436 1/20 0.46
SLC34A1 Q06495 1/20 0.46
SLC34A3 Q8N130 1/20 0.46
SLC20A1 Q8WUM9 1/20 0.46
ALDH1A1 P00352 10/20 0.45
MEN1 O00255 7/20 0.45
KMT2A Q03164 7/20 0.45
RAB9A P51151 3/20 0.45
PKM P14618 2/20 0.45
POLB P06746 4/20 0.42
MAPK14 Q16539 4/20 0.42
HPGD P15428 2/20 0.41
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 2/20 0.40
HTT P42858 1/20 0.40
SMO Q99835 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL267254 1.00 MAPT (0.47) MAPTKDM4ESLC34A2SLC34A1SLC34A3
SCHEMBL270234 0.94 SLC34A2 (0.48) MAPTKDM4ESLC34A2SLC34A1SLC34A3
SCHEMBL270235 0.94 SLC34A2 (0.48) MAPTKDM4ESLC34A2SLC34A1SLC34A3
SCHEMBL267353 0.93 SLC34A2 (0.47) MAPTKDM4ESLC34A2SLC34A1SLC34A3
SCHEMBL267352 0.93 SLC34A2 (0.47) MAPTKDM4ESLC34A2SLC34A1SLC34A3
SCHEMBL266687 0.92 SLC34A2 (0.46) MAPTKDM4ESLC34A2SLC34A1SLC34A3
SCHEMBL266686 0.92 SLC34A2 (0.46) MAPTKDM4ESLC34A2SLC34A1SLC34A3
SCHEMBL268326 0.91 SLC34A2 (0.46) MAPTKDM4ESLC34A2SLC34A1SLC34A3
SCHEMBL268327 0.91 SLC34A2 (0.46) MAPTKDM4ESLC34A2SLC34A1SLC34A3
SCHEMBL269502 0.90 KDM4E (0.49) MAPTKDM4ESLC34A2SLC34A1SLC34A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 MAPT 4195/4885KDM4E 4468/4885SLC34A2 6/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 MAPT 4648/4885KDM4E 4535/4885SLC34A2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.